EP2004237A1 - Thérapie ciblée - Google Patents

Thérapie ciblée

Info

Publication number
EP2004237A1
EP2004237A1 EP07732316A EP07732316A EP2004237A1 EP 2004237 A1 EP2004237 A1 EP 2004237A1 EP 07732316 A EP07732316 A EP 07732316A EP 07732316 A EP07732316 A EP 07732316A EP 2004237 A1 EP2004237 A1 EP 2004237A1
Authority
EP
European Patent Office
Prior art keywords
monocyte
derived cell
gene
cell
magnetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07732316A
Other languages
German (de)
English (en)
Inventor
Jon Dobson
Claire Lewis
Helen Byrne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keele University
Original Assignee
University of Sheffield
University of Nottingham
Keele University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606660A external-priority patent/GB0606660D0/en
Application filed by University of Sheffield, University of Nottingham, Keele University filed Critical University of Sheffield
Publication of EP2004237A1 publication Critical patent/EP2004237A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates

Definitions

  • the present invention relates to cells, in particular macrophages, containing a magnetic material and their use in the treatment of tumours.
  • peptide/protein or a low molecular weight mimetic which binds to either an extracellular protein to inhibit its activity (e.g. an enzyme such as a matrix metalloproteinase) or a molecule in or on the target cell to modify its activity (e.g. the function of tyrosine kinases in the membrane).
  • an extracellular protein e.g. an enzyme such as a matrix metalloproteinase
  • a molecule in or on the target cell e.g. the function of tyrosine kinases in the membrane.
  • tumours eg. tumour cells, or endothelial cells in blood vessels.
  • target cells in tumours eg. tumour cells, or endothelial cells in blood vessels.
  • tumours eg. tumour cells, or endothelial cells in blood vessels.
  • Strategies include replacing mutated or deleted tumour suppressor genes with their wild type counterparts, suppression of the expression/activity of oncogenes (or their downstream effectors), and the delivery of genes encoding cytotoxic proteins, pro-drug activating enzymes, immuno-modulatory or anti-angiogenic proteins to the tumour site (reviewed in Kouraklis, 2000).
  • Oxygen microelectrodes have been used extensively to measure oxygen levels in human tumours. These studies have demonstrated the presence of many areas of hypoxia (low oxygen) and anoxia (no oxygen) in different tumour types, including those of the brain, breast, cervix, head/neck and soft tissue sarcomas (Vaupel et al. 1989; Brown, 2000). Whereas normal tissues typically have median oxygen tensions of 30-70 mmHg, over half of all solid tumours examined exhibited median values of ⁇ 10 mm Hg (with fewer than 10% of measurements in the normal range).
  • hypoxic/anoxic regions appear because the newly formed blood vessels in tumours are often disorganised with many blind ends, incomplete endothelial linings and basement membranes, and have a tendency to collapse (Brown & Giaccia, 1998). Consequently blood flow is sluggish and irregular and the delivery of oxygen and nutrients is poor to many regions of the tumour.
  • the rapid expansion and oxygen consumption of tumour cells around these new blood vessels also contributes to the level of hypoxia formed, although once a threshold level of hypoxia is reached, tumour cells in that area stop proliferating and switch to anaerobic glycolysis for energy production (reviewed by Brown, 2000).
  • hypoxic tumour cells are relatively resistant to such conventional anti-cancer therapies as radiotherapy and chemotherapy.
  • Well-oxygenated tumour cells are markedly more responsive to radiotherapy than their hypoxic counterparts because oxygen-derived free radicals potentiate the protein and DNA damage induced by the ionising radiation.
  • Most anti- cancer chemotherapeutic agents only kill tumour cells if they are rapidly proliferating, so the non-proliferative hypoxic fractions of tumours are relatively resistant to their effects.
  • hypoxic tumour cells While in this non-proliferative state, hypoxic tumour cells are also known to secrete cytokines and enzymes to induce the growth of new blood vessels within the tumour, thereby providing oxygen and nutrients for tumour growth as well as increased exit routes for tumour cells into the general circulation. Hypoxia also exerts a selective pressure on tumour cells because only those with an aggressive phenotype (e.g. mutated for the tumour suppressor gene, p53) are able to survive hypoxia, and go on to re-populate the tumour and metastasise to distant sites (Brown & Giaccia, 1998; Brown, 2000). As these hypoxic areas are relatively inaccessible to conventional anti-cancer drugs and gene vectors (due to the absence of a blood supply) there is a need for therapies that are capable of penetrating these regions in tumours.
  • cytokines and enzymes to induce the growth of new blood vessels within the tumour, thereby providing oxygen and nutrients for tumour growth as well as increased exit routes for tumour cells into the general circulation.
  • macrophages would be taken from the bloodstream of a given cancer patient, differentiated into macrophages ex vivo, transfected with a hypoxia-activated therapeutic gene, and then re-infused into the patient. The transfected macrophages are then taken up from the bloodstream into the primary tumour (as well as any secondary tumours present elsewhere in the body) and accumulate in hypoxic tumour areas.
  • a hypoxia-regulated gene eg.
  • a prodrug-activating enzyme such as cytochrome, P450
  • breast tumour multicell spheroids small 3-D tumour masses grown in vitro from breast tumour cell lines, they rapidly migrated into the inner, hypoxic regions of these small tumour masses and expressed the transgene.
  • the P450 enzyme expressed by hypoxic macrophages at the centre of the MTS converted the prodrug into its active, cytotoxic metabolite.
  • a monocyte, or monocyte- derived cell comprising a magnetic material.
  • the monocyte, or monocyte derived cell, of the invention is useful as a vehicle for targeting a therapeutic agent to a diseased material.
  • the cell of the invention is useful in the thermal treatment, for example, hyperthermia, of a tumour.
  • the monocyte derived cell is preferably a macrophage.
  • Macrophages according to the invention are useful in the treatment of diseased material such as a tumour because (i) able to easily penetrate the endothelial walls (ii) naturally migrate into, and accumulate in, poorly vascularised areas, for example in a tumour and (iii) avoid the possibility of embolisation of the blood vessels in the target region due to accumulation of the magnetic material since this will be inside a cellular carrier i.e. the macrophage.
  • magnetic material is used herein to refer to a material that when exposed to a magnetic field either heats or physically moves.
  • the magnetic material takes the form of a magnetic particle, for example a micro- or nano-particle.
  • the magnetic material may be a fluid, for example, a fluid in which magnetic particles are in suspension otherwise known as a ferrofluid.
  • the magnetic particles will generally be spherical or elliptical and have a mean size in the range lnm to lO ⁇ m.
  • the particles may have a mean size of between 5nm and lO ⁇ m, for example between IOnm and l ⁇ m.
  • the particles are nano-particles having a mean size or diameter of, for example, 5000 nm or less, e.g. from 1 nm to 5000 nm, preferably from 1 nm to 1000 nm, more preferably from 1 nm to 300 nm, or from 2 nm to 10 nm.
  • the magnetic material may be inherently magnetic or, alternatively, may be one which reacts in a magnetic field.
  • the magnetic material may be ferromagnetic, antiferromagnetic, ferrimagnetic, antiferrimagnetic or superparamagnetic.
  • the magnetic material may include elemental iron, chromium manganese, cobalt, nickel, or a compound thereof.
  • the iron compound may be an iron salt which may be selected from the group which includes magnetite (Fe 3 O 4 ), maghemite ( ⁇ Fe 2 O 3 ) and greigite (Fe 3 S 4 ), or any combination thereof.
  • the chromium compound may be chromium dioxide.
  • the magnetic material may comprise a biocompatible coating.
  • the biocompatible coating may be a metal, for example gold, a synthetic material or a biological material or a combination thereof.
  • the synthetic coating may be a polymer, copolymer or combination thereof.
  • the polymer may include dextran, polyvinyl alcohol (PVA), polyethylenimine (PEI), or silica.
  • the biocompatible coating may be provided with a biological molecule which may function to facilitate adhesion of the magnetic particle to the monocyte, or monocyte derived cell, of the invention.
  • molecules that can be used to facilitate adhesion include RGD (synthetic peptide containing the arginine-glycine- aspartate sequence motif), transferrin, collagen, fibronectin/f ⁇ brin, ion channel receptors, cell specific integrin receptors or any cell surface antigen.
  • RGD synthetic peptide containing the arginine-glycine- aspartate sequence motif
  • transferrin collagen, fibronectin/f ⁇ brin, ion channel receptors, cell specific integrin receptors or any cell surface antigen.
  • the cell according to the invention may comprise a detectable agent and/or a therapeutic agent.
  • the detectable agent may be a detectable label which may be linked to a therapeutic agent.
  • the detectable agent can be visualised by MPJ.
  • cell, preferably a macrophage, of the invention comprises a therapeutic agent.
  • therapeutic agent is intended to include any agent useful in therapy.
  • the therapeutic agent may include a chemotherapeutic agent, a radiotherapeutic agent, or a gene, or part thereof, (useful in gene therapy).
  • a chemotherapeutic agent may be an agent selected from the group consisting of S phase dependent antimetabolics, capercitabine, cytarabine, doxorubicin, fludarabine, floxuridine, fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, prednisone, procarbazine, thioguanine, M phase dependent vinca alkaloids, vinblastine, vincristine, vinorelbine, podophyllotoxins, etoposide, teniposide, taxanes, doxetaxel, paxlitaxel, G2 phase dependent, bleomycin, irinotecan, mitoxantrone, topotecan, Gl phase dependent, asparaginase, corticosteroids, alkylating agents, nitrogen mustards, mechlorethamine, mustargen, cyclophosphamide, ifosfamide and clorambucil, leuk
  • the radiotherapeutic agent may comprise a radionuclide selected from the group consisting of Molybdenum-99, Technetium-99m, Chromium-51, Copper-64, Dysprosium- 165, Ytterbium- 169, Indium-I l l, Iodine-125, Iodine-131, Irdium-192, Iron-59, Phosphorous-32, Potassium-42, Rhodium-186, Rhenium-188, Samarium-153, Selenium- 75, Sodium-24, Strontium-89, Xenon-133, Xenon-127 and Yttrium-90 or a combination thereof.
  • a radionuclide selected from the group consisting of Molybdenum-99, Technetium-99m, Chromium-51, Copper-64, Dysprosium- 165, Ytterbium- 169, Indium-I l l, Iodine-125, Iodine-131
  • the chemotherapeutic or radiotherapeutic agent may be associated with an antibody, for example a monoclonal antibody.
  • the therapeutic agent may include DNA, RNA, interfering RNA (RNAi), a peptide, polypeptide, an antibody for example a monoclonal antibody or an antibody fragment such as a single chain antibody fragment, an aptamer, a small molecule.
  • Small molecules may include, but are not limited to, peptides, peptidomimetics (e.g. peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e.
  • heteroorganic and organometallic compounds having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.
  • the therapeutic agent is a gene, or a part thereof (referred to hereinafter as a "therapeutic gene").
  • the cell of the invention further comprises a responsive element.
  • a responsive element (otherwise known as a response element) is intended to include a gene, or part thereof, the expression or activity of which is regulated by, or responsive to, conditions specific to the diseased material to be treated.
  • a part of a gene may include a regulatable element of a gene for example an enhancer, promoter or part thereof.
  • the responsive element may be operably linked to a therapeutic gene so as to regulate expression of the therapeutic gene.
  • the responsive element comprises all or part of a therapeutic gene.
  • the responsive element is a therapeutic gene or part thereof.
  • Responsive elements in accordance with the invention include hypoxia inducible elements (“hypoxia response elements”) and anoxia inducible elements (“anoxia response elements”) examples of which are known in the art and include, but are not limited to, hypoxia inducible factor- (HIF-I), activating transcription factor 4 (ATF-4) and the transcription factor, VL30.
  • Hypoxia inducible, or regulated, elements are activated by low levels of oxygen, for example between 1% and 8 % oxygen.
  • Anoxia inducible, or regulated, elements are activated by extremely low levels of oxygen for example less than 0.1% oxygen.
  • the responsive element may be specific to a tumour (hereinafter referred to as a "tumour responsive element") such that the activity or expression of the tumour responsive element is regulated by, or responsive to, conditions in or around a tumour, for example hypoxia, anoxia, low pH (acidic), high pH (basic), hypoglycaemia.
  • a tumour responsive element for example hypoxia, anoxia, low pH (acidic), high pH (basic), hypoglycaemia.
  • the responsive element is hypoxia or anoxia regulated such as described herein.
  • a therapeutic gene, or responsive element, in accordance with the invention may include, but is not limited to, a tumour suppressor gene, antigenic gene, cytotoxic gene, cytostatic gene, cytokine gene, chemokine gene, pharmaceutical protein gene, pro-apoptotic gene, pro-drug activating gene or an anti-angiogenic gene.
  • tumor suppressor gene refers to a nucleotide sequence, the expression of which in the target cell is capable of suppressing the neoplastic phenotype and/or inducing apoptosis.
  • tumor suppressor genes useful in the practice of the present invention include the p53 gene, the APC gene, the DPC-4 gene, the BRCA-I gene, the BRC A-2 gene, the WT-I gene, the retinoblastoma gene (Lee, et al (1987) Nature 329:642), the MMAC-I gene, the adenomatous polyposis coli protein (Albertsen, et al, United States Patent 5,783,666 issued July 21, 1998), the deleted in colon carcinoma (DCC) gene, the MMSC-2 gene, the NF-I gene, nasopharyngeal carcinoma tumor suppressor gene that maps at chromosome 3p21.3.
  • DCC colon carcinoma
  • a particularly preferred adenovirus for therapeutic use is the A/C/N/53 vector encoding the p53 tumor suppressor gene as more fully described in Gregory, et al, United States Patent 5,932,210 issued August 3, 1999, the entire teaching of which is herein incorporated by reference.
  • antigenic genes refers to a nucleotide sequence, the expression of which in the target cells results in the production of a cell surface antigenic protein capable of recognition by the immune system.
  • antigenic genes include carcinoembryonic antigen (CEA), p53 (as described in Levine, A. PCT International Publication No. WO94/02167 published February 3, 1994).
  • CEA carcinoembryonic antigen
  • p53 as described in Levine, A. PCT International Publication No. WO94/02167 published February 3, 1994.
  • the antigenic gene may be fused to the MHC class I antigen.
  • the antigenic gene is derived from a tumour cell specific antigen. Ideally a tumour rejection antigen.
  • Tumour rejection antigens are well known in the art and include, by example and not by way of limitation, the MAGE, BAGE, GAGE and DAGE families of tumour rejection antigens, see Schulz et al Proc Natl Acad Sci USA, 1991, 88, pp991-993.
  • tumour cells produce a number of tumour cell specific antigens, some of which are presented at the tumour cell surface. These are generally referred to as tumour rejection antigens and are derived from larger polypeptides referred to as tumour rejection antigen precursors.
  • tumour rejection antigens are presented via HLA' s to the immune system. The immune system recognises these molecules as foreign and naturally selects and destroys cells expressing these antigens. If a transformed cell escapes detection and becomes established a tumour develops.
  • Vaccines have been developed based on dominant tumour rejection antigen's to provide individuals with a preformed defence to the establishment of a tumour.
  • cytotoxic gene refers to nucleotide sequence, the expression of which in a cell produces a toxic effect.
  • examples of such cytotoxic genes include nucleotide sequences encoding pseudomonas exotoxin, ricin toxin, diptheria toxin, and the like.
  • cytostatic gene refers to nucleotide sequence, the expression of which in a cell produces an arrest in the cell cycle.
  • examples of such cytostatic genes include p21, the retinoblastoma gene, the E2F-Rb gene, genes encoding cyclin dependent kinase inhibitors such as P 16, pi 5, pi 8 and pi 9, the growth arrest specific homeobox (GAX) gene as described in Branellec, et al. (PCT Publication WO97/16459 published May 9, 1997 and PCT Publication WO96/30385 published October 3, 1996).
  • cytokine gene refers to a nucleotide sequence, the expression of which in a cell produces a cytokine.
  • cytokines include GM-CSF, the interleukins, especially IL-I, IL-2, IL-4, IL- 12, IL-IO, IL- 19, IL-20, interferons of the ⁇ , ⁇ and ⁇ subtypes, consensus interferons and especially interferon ⁇ -2b and fusions such as interferon ⁇ -2 ⁇ -l.
  • chemokine gene refers to a nucleotide sequence, the expression of which in a cell produces a cytokine.
  • chemokine refers to a group of structurally related low- molecular cytokines weight factors secreted by cells are structurally related having mitogenic, chemotactic or inflammatory activities. They are primarily cationic proteins of 70 to 100 amino acid residues that share four conserved cysteine. These proteins can be sorted into two groups based on the spacing of the two amino-terminal cysteines. In the first group, the two cysteines are separated by a single residue (C-x-C), while in the second group, they are adjacent (C-C).
  • member of the 'C-x-C chemokines include but are not limited to platelet factor 4 (PF4), platelet basic protein (PBP), interleukin-8 (IL-8), melanoma growth stimulatory activity protein (MGSA), macrophage inflammatory protein 2 (MIP-2), mouse Mig (ml 19), chicken 9E3 (or pCEF-4), pig alveolar macrophage chemotactic factors I and II (AMCF-I and -II), pre-B cell growth stimulating factor (PBSF),and IPlO.
  • PF4 platelet factor 4
  • PBP platelet basic protein
  • IL-8 interleukin-8
  • MGSA melanoma growth stimulatory activity protein
  • MIP-2 macrophage inflammatory protein 2
  • mouse Mig mouse Mig
  • chicken 9E3 or pCEF-4
  • pig alveolar macrophage chemotactic factors I and II AMCF-I and -II
  • PBSF pre-B cell growth stimulating factor
  • Examples of members of the 'C-C group include but are not limited to monocyte chemotactic protein 1 (MCP-I), monocyte chemotactic protein 2 (MCP-2), monocyte chemotactic protein 3 (MCP-3), monocyte chemotactic protein 4 (MCP-4), macrophage inflammatory protein 1 ⁇ (MIP- 1- ⁇ ), macrophage inflammatory protein 1 ⁇ (MIP- 1- ⁇ ), macrophage inflammatory protein 1- ⁇ (MIP- 1- ⁇ ), macrophage inflammatory protein 3 ⁇ (MIP-3- ⁇ ), macrophage inflammatory protein 3 ⁇ (MIP-3- ⁇ ), chemokine (ELC) 3 macrophage inflammatory protein-4 (MIP-4), macrophage inflammatory protein 5 (MIP-5), LD78 ⁇ , RANTES, SIS-epsilon (p500), thymus and activation-regulated chemokine (TARC), eotaxin, 1-309, human protein HCC-l/NCC-2, human protein HCC-3, mouse protein
  • pharmaceutical protein gene refers to nucleotide sequence, the expression of which results in the production of protein have pharmaceutically effect in the target cell.
  • pharmaceutical genes include the proinsulin gene and analogs (as described in PCT International Patent Application No. WO98/31397, growth hormone gene, dopamine, serotonin, epidermal growth factor, GABA, ACTH, NGF, VEGF (to increase blood perfusion to target tissue, induce angiogenesis, PCT publication WO98/32859 published July 30, 1998), thrombospondin etc.
  • the pharmaceutical protein gene may encompass immunoreactive proteins such as antibodies, Fab fragments, Fv fragments, humanized antibodies, chimeric antibodies, single chain antibodies, and human antibodies derived from non-human sources.
  • pro-apoptotic gene refers to a nucleotide sequence, the expression thereof results in the induction of the programmed cell death pathway of the cell.
  • pro-apoptotic genes include p53, adenovirus E3-11.6K(10.5K), the adenovirus E4orf4 gene, p53 pathway genes, and genes encoding the caspases.
  • pro-drug is intended to any non-therapeutic compound which is a latent therapeutic compound that is capable of being converted to a therapeutic compound.
  • pro-drug activating genes refers to nucleotide sequences, the expression of which, results in the production of protein capable of converting a non-therapeutic compound (i.e. a pro-drug) into a therapeutic compound (i.e. a drug) which renders the cell susceptible to killing by external factors or causes a toxic condition in the cell.
  • cytosine deaminase gene is the cytosine deaminase gene. Cytosine deaminase converts 5-fluorocytosine to 5 fluorouracil, a potent antitumor agent).
  • the lysis of the tumor cell provides a localized burst of cytosine deaminase capable of converting 5FC to 5FU at the localized point of the tumor resulting in the killing of many surrounding tumor cells.
  • the thymidine kinase (TK) gene in which the cells expressing the TK gene product are susceptible to selective killing by the administration of gancyclovir may be employed.
  • the pro-drug activating gene may be the hypoxia regulated gene, cytochrome p450.
  • anti-angiogenic genes refers to a nucleotide sequence, the expression of which results in the extracellular secretion of anti-angiogenic factors.
  • Anti-angiogenesis factors include angiostatin, inhibitors of vascular endothelial growth factor (VEGF) such as Tie 2 (as described in PNAS(USA)(1998) 95:8795-8800), endostatin.
  • VEGF vascular endothelial growth factor
  • the reference to the p53 gene includes not only the wild type protein but also modified p53 proteins.
  • modified p53 proteins include modifications to p53 to increase nuclear retention, deletions such as the D 13-19 amino acids to eliminate the calpain consensus cleavage site (Kubbutat and Vousden (1997) MoI. Cell. Biol.
  • therapeutic transgene may be secreted into the media or localized to particular intracellular locations by inclusion of a targeting moiety such as a signal peptide or nuclear localization signal (NLS).
  • a targeting moiety such as a signal peptide or nuclear localization signal (NLS).
  • a cell such as a macrophage
  • a pharmaceutical composition comprising a cell, preferably a macrophage, according to the invention.
  • the pharmaceutical compositions of the present invention are administered in pharmaceutically acceptable preparations.
  • Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents for example a cheniotherapeutic agent.
  • the therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time.
  • the administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal.
  • compositions of the invention are administered in effective amounts.
  • An "effective amount" is that amount of a composition that alone, or together with further doses, produces the desired response.
  • the desired response is inhibiting the progression of the disease. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods of the invention discussed herein.
  • Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.
  • compositions used in the foregoing methods preferably are sterile and contain an effective amount of nucleic acid for producing the desired response in a unit of weight or volume suitable for administration to a patient.
  • the response can, for example, be measured by determining regression of a tumour, decrease of disease symptoms, modulation of apoptosis, etc.
  • the doses of therapeutic agent administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.
  • doses of therapeutic agent of between InM - l ⁇ M generally will be formulated and administered according to standard procedures.
  • doses can range from InM- 50OnM, 5nM-200nM, 1OnM- 10OnM.
  • Other protocols for the administration of compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of injections, sites of injections, mode of administration (e.g., intra-tumour) and the like vary from the foregoing.
  • Administration of compositions to mammals other than humans is carried out under substantially the same conditions as described above.
  • a subject, as used herein, is a mammal, preferably a human, and including a non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent.
  • the pharmaceutical preparations of the invention When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions.
  • pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.
  • the salts When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.
  • Such pharmacologically and pharmaceutically- acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like.
  • pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.
  • compositions may be combined, if desired, with a pharmaceutically-acceptable carrier.
  • pharmaceutically-acceptable carrier means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human.
  • carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
  • the components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.
  • the pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.
  • suitable buffering agents including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.
  • compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
  • suitable preservatives such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
  • compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
  • compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound.
  • Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as syrup, elixir or an emulsion.
  • Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of therapeutic agent, which is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation also may be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, for example, as a solution in I 5 3 -butane diol.
  • a nontoxic parenterally-acceptable diluent or solvent for example, as a solution in I 5 3 -butane diol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono-or di-glycerides.
  • fatty acids such as oleic acid may be used in the preparation of injectables.
  • Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.
  • a further aspect of the invention provides a magnetic material composition, the composition comprising a macrophage comprising a magnetic material associated with a first therapy, and a therapeutic gene associated with a second therapy.
  • the first therapy may be thermotherapy, for example hyperthermia.
  • the second therapy may be gene therapy.
  • the composition may also comprise at least one other agent, for example a prodrug, associated with the therapeutic gene.
  • a further aspect of the invention provides a method of preparing a cell according to the invention, the method comprising introducing the magnetic material into the monocyte or monocyte derived cell.
  • the cell is a macrophage and the magnetic material is accumulated by the macrophage during culture of the macrophage with the magnetic material.
  • the method includes the step of introducing the therapeutic agent into the cell according to the invention.
  • the therapeutic agent is a therapeutic gene
  • the cell typically a macrophage
  • a gene transfer vector may include liposomes and viral vectors.
  • Viral vectors may include adenovirus, retrovirus, adeno-associated virus and sendai virus. High level gene transfer to macrophages may be achieved using such replication-deficient adenoviruses as adv5
  • a method for targeting a cell, preferably a macrophage, according to the invention to a diseased material in a subject comprising administering the monocyte, or monocyte derived cell, to the subject's body, body part, tissue or body fluid and exposing the monocyte, or monocyte derived cell, to a magnetic field.
  • the administration of a magnetic field source serves to aid the macrophages natural homing ability in directing the macrophage to the diseased target.
  • the macrophage serves to target the magnetic material to, and locating the magnetic material in, the diseased material.
  • the magnetic material couples to the field and is heated.
  • diseased material is intended to include diseased, disease- causing (such as pathogens implicated in disease) or undesirable material in the body or body part of a subject.
  • a method of targeting a magnetic material to a diseased material in a subject comprising the administration of a cell according to the invention to the subject's body, body part, tissue or body fluid only.
  • the method of the invention is useful in targeted thermotherapy whereby the administration of a magnetic field, preferably a time- varying magnetic field, serves to excite/heat the magnetic material of cell of the invention resulting in the release of thermal energy.
  • the methods of the invention may be useful in the in vivo or ex vivo targeting of the magnetic material containing cells to a diseased material in a subject.
  • a further aspect of the invention provides a targeted thermotherapy system for treating diseased material in a subject, the system comprising: i) a cell, preferably a macrophage, according to the first aspect of the invention; and ii) a magnetic energy source to heat the magnetic material within the cell.
  • a further aspect of the invention provides a method of treating a diseased material in a subject the method comprising the administration of a cell according to the invention, preferably a macrophage, to a subject's body, body part, tissue or body fluid and the administration of a magnetic energy source to destroy, rupture or inactivate the diseased material.
  • the method of the invention provides for the targeted generation of heat to/at the diseased material.
  • Such heat therapy is referred to as thermotherapy or hyperthermia.
  • temperatures in a range of from about 4O 0 C to about 46 0 C cause irreversible damage to cells because it induces necrosis (typically called “thermo-ablation”) and/or heat-shock response in cells (classical hyperthermia-apoptosis) leading to cell death.
  • a method of treating a diseased material in a subject comprising the administration of a cell according to the invention, preferably a macrophage, to a subject's body, body part, tissue or body fluid.
  • the method is gene therapy and the cell comprises a therapeutic gene such that the gene is administered to the subject's body, body part, tissue or body fluid.
  • the method of gene therapy may include the administration of at least one other agent, for example a pro-drug, associated with the therapeutic gene.
  • the at least one other agent may be administered prior to, during or after the administration of the therapeutic gene.
  • Macrophages have been shown to migrate into the hypoxic regions of tumours. Furthermore, by the incorporation of magnetic material into the macrophages, the macrophages are magnetically targeted to these regions of the tumour. Where the macrophages comprise a hypoxia-regulated therapeutic gene, the therapeutic gene will be expressed in the hypoxic regions of the tumour.
  • the present invention also pertains to a method of treating a diseased material in a subject using a combination of targeted thermotherapy and gene therapy.
  • the targeted thermotherapy may be administered to a subject before, during, after the gene therapy, or a combination thereof.
  • the magnetic energy source is typically a magnetic field.
  • the magnetic field may be provided by a magnet or array of magnets.
  • the magnet or array may be a permanent magnet or an electromagnet.
  • the magnetic field may be static or alternating, for example oscillating. Static magnetic fields are typically used when targeting the magnetic material to a diseased target; alternating magnetic fields are typically used when heating the magnetic material.
  • the magnetic field may be administered directly into the subject's body, body part, tissue or body fluid (such as blood, blood plasma, blood serum or bone marrow), or extracorporeally to the subject's body, organ or body fluid.
  • the magnetic field is applied externally to the body, for example over a tumour site, so as to tend to move the magnetic material (e.g.
  • the magnetic field is used to target and enhance the uptake of the magnetic material containing macrophages into the tumour.
  • the magnetic field may be applied in vivo, for example, the magnetic field may be provided by an implantable magnet implanted in the subject's body.
  • the macrophages are capable of destroying the tumour, and macrophage itself, via magnetic particle hyperthermia.
  • a cell preferably a macrophage, according to the invention in the manufacture of a medicament for the treatment of a diseased material.
  • the therapeutic methods and uses of the invention may be useful in the treatment of cancer, AIDS, adverse angiogenesis, cardiovascular plaque, vascular plaque, calcified plaque, restenosis, amyloidosis, tuberculosis, obesity, arthritis.
  • the diseased material to be treated is cancer.
  • cancer refers to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth.
  • the term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness.
  • cancer includes malignancies of the various organ systems, such as those affecting, for example, lung, breast, thyroid, lymphoid, gastrointestinal, and genito-urinary tract, as well as adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumours, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
  • carcinoma is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas.
  • exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head (including brain) and neck, colon, skin and ovary.
  • carcinosarcomas e.g., which include malignant tumours composed of carcinomatous and sarcomatous tissues.
  • an “adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.
  • the term “sarcoma” is art recognized and refers to malignant tumors of mesenchymal derivation.
  • the diseased material is a tumour.
  • tumour is intended to include tumour cells and the vasculature of the tumour, for example the endothelial cells in the blood vessels of the tumour.
  • the tumour may be benign or malignant.
  • the tumour is malignant.
  • treatment of cancer is intended to include the killing of cancer cells or making tumours more sensitive to the effects of radiation and or chemotherapy.
  • treatment of a tumour is intended to include any treatment that destroys or inactivates tumour cells or inhibits or destroys the vasculature of the tumour
  • a yet further aspect of the invention provides a method of treating the body, body part, tissue, cell, or body fluid of a subject, the method comprising the step of medically imaging the body, body part, tissue, cell or body fluid; administering a cell according to the first aspect of the invention and exposing the cell to a magnetic field.
  • the administration of the cell according to the invention may occur prior to, during or after the medical imaging, or a combination thereof.
  • Figure 1 A primary human macrophage (red membrane dye), 7 days post-internalization of 1-2 ⁇ m RGD-coated magnetic particles (yellow).
  • FIG. 2 Transverse section of a T47D spheroid, with a central necrotic area (N) of cell debris, surrounded by two layers of viable cells.
  • the outer layer blue
  • the inner layer is hypoxic (red staining is for the hypoxic marker, HIF-l ⁇ . See arrows).
  • Figure 3 Section of a human breast tumour spheroid, showing macrophage accumulation (stained brown, see arrows) in the inner hypoxic rim around the central necrotic area (N).
  • Biocompatible magnetic nanoparticles primarily composed of a magnetite (Fe 3 O 4 ) and/or maghemite ( ⁇ Fe 2 O 3 ) core with either a silica, dextran, or PVA coating are synthesised following the methods outlined by them in Santra et al. (2001) and Pardoe et al. (2001).
  • Commercially available magnetic micro- and nanoparticles with varying surface chemistry are also used to load the macrophages.
  • the magnetic properties of all particles used in these experiments are characterized with a Quantum Designs MPMS Superconducting Quantum Interference Device (SQUID) magnetometer and these parameters are used as input into the mathematical modelling discussed below.
  • SQUID Quantum Designs MPMS Superconducting Quantum Interference Device
  • Coatings and Particle Loading - The polymer coating of the magnetic particles is functionalized and coated with molecules which facilitate membrane adhesion and phagocytosis.
  • Isolation and non-adherent culture of human macrophages - Monocytes are isolated from blood samples taken from healthy volunteers. Blood is collected into sodium citrate (final volume 10%) and layered onto a Ficoll gradient. After centrifugation, the mononuclear cell layer is collected and monocytes purified from this fraction using CD 14 magnetic beads as described by us previously in Griffiths et al. (2000). These cells are then cultured in 5% autologous serum/RPMI in non-adherent, sterile Teflon bags for a further 7 days until differentiated into macrophages. Our previous immunohistochemical staining for the pan macrophage marker, CD68, has indicated that >95% of the cells present in these 7day cultures are monocyte-derived macrophages (MDMs) (Burke et al. 2001 & 2003).
  • MDMs monocyte-derived macrophages
  • Tumour spheroids are grown in non-adherent, agarose overlay cultures to 800-900 um in diameter from the breast cancer cell line, T47D. This results in spheroids with outer, well-oxygenated cell layers (approx. 200 um wide) and an inner, hypoxic area of viable tumour cells (200-250 urn wide) around a central, necrotic area (Fig.2).
  • Fig.2 We have previously used antibodies to HIF-I to stain hypoxic tumour cells in the inner hypoxic rim of spheroids (Fig.2) and shown macrophages to accumulate in these areas following 1-3 days of co-culture with primary MDMs (see Fig. 3).
  • Spheroids are co- cultured with 50,000 primary human macrophages.
  • the total number of macrophages infiltrating spheroids is assessed using flow cytometry (i.e. collagenase dispersal of the spheroids followed by FACS analysis using CD14/CD68 antibodies).
  • the distribution of macrophages inside spheroids is assessed in parallel cultures using immunohistochernistry for CD68 on wax/frozen sections of MTS. This confirms that macrophages are accumulating specifically in the inner, hypoxic areas of spheroids in these co-cultures.
  • Magnetic targeting of spheroids External rare earth magnets are used to stimulate uptake of magnetic macrophages to the above 'still' cultures of spheroids in 96 well plates. These magnets produce high field/gradient products which exert a translational force on the magnetic particles internalized by macrophages. Optimization of the targeting parameters (field strength, gradient, particle size and magnetic properties) is accomplished via mathematical modelling and magnetic field profiles are mapped using a Redcliffe Diagnostics MagScan system. Once this has been done using non-transfected macrophages, macrophages bearing reporter or therapeutic genes are used.
  • Gene transfer to macrophages - Macrophages are infected with a replication defective adenovirus bearing a reporter gene, LacZ under the control of either a constitutively active (CMV) promoter or a hypoxia-regulated response element (HRE).
  • CMV constitutively active
  • HRE hypoxia-regulated response element
  • the latter is only expressed when macrophages migrate into the central, hypoxic areas of tumour spheroids (as described previously in Griffith et al. 2000 & Burke et al. 2003).
  • High level gene transfer to macrophages (>85% efficiency in CEL' s laboratory) is achieved using such replication-deficient adenoviruses as adv5 (Griffith et al. 2000).
  • HRE hypoxia response element
  • CMV-driven ⁇ -gal expression by macrophages is then quantified in whole, macrophage-infiltrated spheroids using ⁇ -GLO FACS analysis - ie. following enzymatic dispersion of cells in spheroids.
  • HRE-driven ⁇ -gal expression is visualised in the inner, hypoxic areas of spheroids using x-gal staining of sections of frozen spheroids.
  • the next stage is to replace the reporter gene (LacZ) by a therapeutic gene such as P450 (Griffiths et al. 2000), or the cDNA encoding the potent, new anti-angiogenic peptide, Alphastatin (Staton et al. 2004), and the study repeated to see if the use of magnetic particles also increases the expression of these genes in hypoxic tumour areas.
  • a therapeutic gene such as P450 (Griffiths et al. 2000), or the cDNA encoding the potent, new anti-angiogenic peptide, Alphastatin (Staton et al. 2004)
  • Magnetic particle hyperthermia is used in two sets of experiments. In the first case, it is used in combination with the gene therapy technique described above in order to try to destroy the loaded macrophages after the transfection of therapeutic and reporter genes.
  • this technique prevents the macrophages from promoting cancer growth if they are allowed to remain in the tumour for extended periods of time as previously described.
  • this technique is used in a more classical magnetic particle hyperthermia sense, where the objective is not the delivery and transfection of therapeutic genes but rather the destruction of the tumour mass via heating.
  • Macrophages are loaded with magnetic particles and introduced into an artery feeding the tumour region.
  • a steady magnetic field with maximum intensity close to the tumour, is used to pull the macrophages out of suspension and onto the endothelial walls.
  • the main aim of the modelling at this stage is to predict the types of vessel, and the positions of vessels, in which the macrophages come out of suspension.
  • the modelling involves balancing Stokes' drag (arising from the interaction of macrophage with the blood flow in the vessel) with magnetic force on a macrophage.
  • Outcomes of the modelling include the design of magnetic fields (strengths and intensity distribution) and the level of magnetic particle doping necessary to optimise the distribution of macrophages over the vasculature of the tumour region.
  • a localised oscillating magnetic field is applied to the tumour.
  • the magnetisation of the magnetic particles within the macrophages undergo hysteresis, with the oscillations of the field, and release thermal energy as they do so.
  • the release of energy causes localised heating which is used to destroy tumour cells.
  • This heating is modelled by a diffusion equation for the temperature with sources terms at the positions of macrophages (and hence magnetic particles).
  • the strength of these source terms is estimated by exploiting the magnetic hysteresis curve for magnetite.
  • the model is used to calculate the strength of magnetic field that should be applied to the tumour to give the desired heating effects.
  • RGD-coated biocompatible magnetic microparticles consisting of a magnetite (Fe 3 O 4 ) and maghemite ( ⁇ Fe 2 O 3 ) core were prepared in using methods similar to those outlined previously by them (Cartmell et al., 2002, 2003; Hughes et al., 2003).
  • Blood monocytes were isolated from human blood and allowed to differentiate in culture into macrophages for 8 days.
  • the cells membranes were then labelled with the red fluorescent cell tracker dye PHK-26 (Sigma) (using the manufacturers guidelines), and incubated with the magnetic microparticles (25 ⁇ g/ml). Cells were incubated with the particles overnight to allow their phagocytosis.
  • Murdoch C Gouinnidis A & Lewis CE. (2004). Mechnanism regulating the recruitment of macrophages into human tumours: accumulation in hypoxic/necotic areas. Blood (submitted; invited review).
  • Pulfer SK, Gallo JM (1998) Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J. Drug. Target. 6: 215-227.
  • Magnetic microspheres a model system for site specific drug delivery in vivo. Proc. Soc. Exp. Biol. Med. 58: 141-146.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un monocyte, ou une cellule dérivée d'un monocyte, tel un macrophage, comportant un matériel magnétique, tel une particule magnétique ou un ferrofluide, ayant de préférence un revêtement biocompatible, administré de façon ciblée à un tissu malade dans un sujet. Une source d'énergie magnétique peut être appliquée ensuite au sujet pour détruire, rompre ou désactiver le tissu malade. En variante, le monocyte ou la cellule dérivée du monocyte peut inclure en outre un agent thérapeutique qui est ainsi ciblé sur le tissu malade.
EP07732316A 2006-04-03 2007-04-03 Thérapie ciblée Withdrawn EP2004237A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78918506P 2006-04-03 2006-04-03
GB0606660A GB0606660D0 (en) 2006-04-03 2006-04-03 Targeted Therapy
PCT/GB2007/001272 WO2007113572A1 (fr) 2006-04-03 2007-04-03 Thérapie ciblée

Publications (1)

Publication Number Publication Date
EP2004237A1 true EP2004237A1 (fr) 2008-12-24

Family

ID=38179577

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07732316A Withdrawn EP2004237A1 (fr) 2006-04-03 2007-04-03 Thérapie ciblée

Country Status (4)

Country Link
US (1) US20090123366A1 (fr)
EP (1) EP2004237A1 (fr)
AU (1) AU2007232356A1 (fr)
WO (1) WO2007113572A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
WO2009076465A1 (fr) * 2007-12-11 2009-06-18 University Of Maryland, College Park Procédés et systèmes de concentration magnétique d'agents thérapeutiques, diagnostiques ou prophylactiques sur des cibles profondes
US8579787B2 (en) 2008-05-19 2013-11-12 University Of Maryland College Park Methods and systems for using therapeutic, diagnostic or prophylactic magnetic agents
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9669200B2 (en) 2010-08-06 2017-06-06 Boston Scientific Scimed, Inc. Systems and methods for the treatment of pelvic disorders including magnetic particulates
US9180172B2 (en) 2010-12-15 2015-11-10 Ams Research Corporation Treatment of Peyronies disease
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
EP2683440B1 (fr) * 2011-03-10 2015-11-04 MagForce AG Outil de simulation assisté par ordinateur destiné à aider un utilisateur lorsqu'il planifie une thermothérapie
US20130197296A1 (en) * 2012-01-13 2013-08-01 Karl-Heinz Ott Removing Cells from an Organism
KR20130084091A (ko) 2012-01-16 2013-07-24 삼성전자주식회사 화상형성장치
US20130302252A1 (en) 2012-05-11 2013-11-14 University Of Washington Through Its Center For Commercialization Polyarginine-coated magnetic nanovector and methods of use thereof
WO2013184527A1 (fr) 2012-06-05 2013-12-12 Capricor, Inc. Procédés optimisés pour générer des cellules souches cardiaques à partir de tissu cardiaque et leur utilisation dans une thérapie cardiaque
GB2505072A (en) 2012-07-06 2014-02-19 Box Inc Identifying users and collaborators as search results in a cloud-based system
JP6433896B2 (ja) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
JP6878274B2 (ja) 2014-10-03 2021-05-26 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
GB201504251D0 (en) * 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
PL412787A1 (pl) 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
EP3402543B1 (fr) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cellules dérivées de cardiosphères et exosomes sécrétés par ces cellules dans le traitement d'une insuffisance cardiaque à fraction d'éjection préservée
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP3612191A4 (fr) 2017-04-19 2020-12-30 Cedars-Sinai Medical Center Méthodes et compositions pour traiter une dystrophie musculaire squelettique
EP3727351A4 (fr) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center Vésicules extracellulaires modifiées pour une administration tissulaire améliorée
GB201818110D0 (en) * 2018-11-06 2018-12-19 Macrophox Ltd Monocytes for cancer targeting
GB2605276A (en) 2019-09-03 2022-09-28 Myeloid Therapeutics Inc Methods and compositions for genomic integration
AU2020403155A1 (en) * 2019-12-11 2022-06-30 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods for manufacture and uses thereof
GB2617474A (en) 2020-11-04 2023-10-11 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334312A (en) * 1996-10-09 2000-10-27 Oxford Biomedica Ltd Use of mononuclear phagocytes and a binding agent in therapeutic drug delivery
US7282479B2 (en) * 2003-03-31 2007-10-16 Ttc Co., Ltd. Hyperthermia agent for malignant tumor comprising cytokine and magnetic fine particles
GB0329310D0 (en) * 2003-12-18 2004-01-21 Univ Keele Method
WO2005065282A2 (fr) * 2003-12-31 2005-07-21 The Regents Of The University Of California Procedes et articles de traitement magnetique a distance de cancers et autres maladies et procedes pour faire fonctionner un tel article
WO2005105035A2 (fr) * 2004-04-29 2005-11-10 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Systeme d'administration
WO2007016501A2 (fr) * 2005-08-01 2007-02-08 The University Of Chicago Compositions et procede pour administrer des agents therapeutiques de maniere ciblee et specifique a un tissu

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M MUTHANA ET AL: "A novel magnetic approach to enhance the efficacy of cell-based gene therapies", GENE THERAPY, vol. 15, no. 12, 1 June 2008 (2008-06-01), pages 902 - 910, XP055061888, ISSN: 0969-7128, DOI: 10.1038/gt.2008.57 *
PAULINE VERDIJK ET AL: "Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines", INTERNATIONAL JOURNAL OF CANCER, vol. 120, no. 5, 1 March 2007 (2007-03-01), pages 978 - 984, XP055061891, ISSN: 0020-7136, DOI: 10.1002/ijc.22385 *
See also references of WO2007113572A1 *

Also Published As

Publication number Publication date
WO2007113572A1 (fr) 2007-10-11
AU2007232356A1 (en) 2007-10-11
US20090123366A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
US20090123366A1 (en) Targeted Therapy
Tong et al. Magnetic iron oxide nanoparticles for disease detection and therapy
US20210060101A1 (en) Tropic cell based virotherapy for the treatment of cancer
Dobson Magnetic micro-and nano-particle-based targeting for drug and gene delivery
Plank et al. Magnetically enhanced nucleic acid delivery. Ten years of magnetofection—Progress and prospects
Su et al. Design strategies and applications of circulating cell-mediated drug delivery systems
Prijic et al. Magnetic nanoparticles as targeted delivery systems in oncology
US20030219785A1 (en) Targeted drug delivery methods
Huang et al. MnCaCs-biomineralized oncolytic virus for bimodal imaging-guided and synergistically enhanced anticancer therapy
Lu et al. Photoluminescent mesoporous silicon nanoparticles with siCCR2 improve the effects of mesenchymal stromal cell transplantation after acute myocardial infarction
Chen et al. Inhibitory effect of neuropilin-1 monoclonal antibody (NRP-1 MAb) on glioma tumor in mice
Gupta et al. Cancer treatment with nano-diamonds
KR102657640B1 (ko) 종양분해성 단순포진 바이러스 감염된 세포
Yip et al. Neural stem cells as novel cancer therapeutic vehicles
Garg Filamentous bacteriophage: A prospective platform for targeting drugs in phage-mediated cancer therapy
Chen et al. Smart magnetotactic bacteria enable the inhibition of neuroblastoma under an alternating magnetic field
KR102267981B1 (ko) 생체기반 유기체를 이용한 자기구동 마이크로로봇
Chen et al. Polyvalent spherical aptamer engineered macrophages: X-ray-actuated phenotypic transformation for tumor immunotherapy
Howard et al. Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus
Zhao et al. The application of nanomedicine in clinical settings
Wu et al. Living cell for drug delivery
Wang et al. Microvesicles as drug delivery systems: A new frontier for bionic therapeutics in cancer
Wang et al. New Strategies and In Vivo Monitoring Methods for Stem Cell‐Based Anticancer Therapies
US20020061294A1 (en) Mononuclear phagocytes in therapeutic drug delivery
CN101495151A (zh) 靶向治疗

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20100512

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KEELE UNIVERSITY

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101AFI20150126BHEP

Ipc: C12N 5/07 20100101ALI20150126BHEP

INTG Intention to grant announced

Effective date: 20150224

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DOBSON, JON

Inventor name: BYRNE, HELEN

Inventor name: LEWIS, CLAIRE

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151103